"Many people speculated that the SARAH study, reported today, was going to miss it's primary endpoint as the group of patients was too mixed."
Hi PB, can you give us a little more colour behind that statement? It's the first I've heard of it although I admit I'm not that close to the medical community.
SRX Price at posting:
$17.00 Sentiment: None Disclosure: Held
